Climb Bio, Inc.
2.0800+0.00 (+0%)
Oct 29, 4:00:01 PM EDT · NasdaqGM · CLYM · USD
Key Stats
Market Cap
140.95MP/E (TTM)
-Basic EPS (TTM)
-0.02Dividend Yield
0%Recent Filings
8-K
Long-term budoprutug data released
Climb Bio announced long-term follow-up data from its Phase 1b trial of budoprutug, showing sustained proteinuria control for up to three years in four primary membranous nephropathy patients after up to four doses. Three patients needed no further immunosuppression. No grade 3 or higher adverse events occurred. This bolsters budoprutug's potential in B-cell diseases, yet regulatory approvals remain uncertain.
8-K
CLYM116 preclinical data shines
Climb Bio unveiled preclinical data on September 29, 2025, showing its CLYM116 anti-APRIL antibody outperforming sibeprenlimab in nonhuman primates, with ~85% subcutaneous bioavailability, a 2-3 times longer half-life, and >70% maximal IgA reduction after a single 6 mg/kg dose. This positions CLYM116 for less frequent dosing in IgA nephropathy, a $10-20B U.S. market needing lifelong therapies. Phase 1 trial starts Q4 2025. Yet risks like regulatory delays loom.
8-K
Q2 loss narrows; trials advance
Climb Bio reported Q2 2025 net loss of $8.7 million, with R&D expenses rising to $6.6 million from $1.0 million year-over-year amid pipeline acceleration. The company dosed first patients in budoprutug trials for ITP and SLE, eyes pMN Phase 2 start soon, and advances CLYM116 toward H2 2025 IND for IgAN. Cash stands at $187.4 million, funding operations through 2027. New CMO Edgar Charles brings immunology expertise. Pipeline momentum builds, yet clinical risks loom.
10-Q
Q2 FY2025 results
Climb Bio narrowed its Q2 net loss to $8.7M from $54.9M a year earlier, as the prior period's $51.7M IPR&D charge from the Tenet acquisition faded, while R&D expenses climbed 529% y/y to $6.6M on budoprutug trial startups and the $9.0M CLYM116 upfront. Operating loss improved 81% y/y to $10.7M, with diluted EPS at -$0.13 versus -$1.81 (derived from 67.6M shares). YTD net loss eased to $29.4M from $56.6M, driven by R&D up 1,018% y/y to $23.9M, offset by $4.5M interest income. Cash and equivalents fell to $22.7M from $87.2M year-end, with $187.4M total liquidity funding operations through 2027; no debt. The January 2025 Mabworks deal closed for $9.0M cash, securing ex-Greater China rights to CLYM116 with up to $862.0M in milestones and low-single-digit royalties. Yet competitors like Novartis and Vera Therapeutics are advancing APRIL inhibitors for IgAN.
8-K
Climb Bio appoints new finance head
Climb Bio appointed Cindy Driscoll as Senior Vice President, Finance and principal financial and accounting officer effective June 17, 2025, replacing interim chief Aoife Brennan and outgoing Chief Accounting Officer Emily Pimblett, who resigns June 30. Driscoll brings biotech finance experience from hC Bioscience and Magenta Therapeutics, with a $355,000 base salary, 35% bonus potential, and a 200,000-share option vesting over four years. This stabilizes leadership amid transition. Severance terms protect her tenure.